Treatment interventions for Parkinson's disease: an evidence based assessment

@article{Rascol2002TreatmentIF,
  title={Treatment interventions for Parkinson's disease: an evidence based assessment},
  author={Olivier Rascol and Christopher G Goetz and William C. Koller and Werner Poewe and Cristina Sampaio},
  journal={The Lancet},
  year={2002},
  volume={359},
  pages={1589-1598}
}
Physical therapy in Parkinson's disease: Evolution and future challenges
TLDR
The professional evolution and scientific validation of physical therapy in PD is reviewed, new strategies to improve the organization of allied health care in PD are discussed, making evidence‐based care available to all PD patients.
Clinical management of Parkinson’s disease dementia: pitfalls and progress
TLDR
The efficacy and some of the problems of medication used for non-motor symptoms, including antiparkinsonian medication, antipsychotics and acetylcholinesterase inhibitors are described.
Current concepts in the diagnosis and management of Parkinson's disease.
  • M. Guttman, S. Kish, Y. Furukawa
  • Psychology, Medicine
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • 2003
TLDR
Treatment during the early stage of Parkinson's disease has evolved, and evidence suggests that dopamine agonist monotherapy may prevent the response fluctuations that are associated with disease progression, but L-dopa therapy, however, remains the most efficacious treatment.
A comprehensive approach to Parkinson's disease
  • S. Brunton
  • Medicine, Psychology
    Postgraduate medicine
  • 2006
TLDR
In this article, Dr Brunton describes the complex presentation of this disease, appropriate drug therapy, drug side effects, and neurosurgical techniques that may be used should drugs fail.
Treatment of Parkinson’s Disease
TLDR
Assessment of treatment options, treatment satisfaction and opinions about treatment improvements in patients with PD and neurologists treating the disease concluded that treatment guidelines need to incorporate QOL aspects and general communication between the health professional and the patient.
Treatment options for non-motor symptoms in late-stage Parkinson's disease
TLDR
The objective of this study was to review the treatment options for Parkinson's disease dementia, psychosis, falls, bone fractures, joint and skeletal deformities, pain, orthostatic hypotension, gastrointestinal abnormalities and urological dysfunction in late-stage Parkinson's Disease.
Managing the critical problems of advanced Parkinson’s disease
  • F. Stocchi
  • Medicine
    Expert review of neurotherapeutics
  • 2002
TLDR
An overview of the Parkinson’s disease specialist's strategies for coping with the development of motor complications, such as end-of-dose wearing-off and dyskinesias, following long-term therapy is provided.
Evaluating drug treatments for Parkinson's disease: how good are the trials?
TLDR
It is made the case that most trials of drug treatment for Parkinson's disease have crucial methodological faults—and provide little reliable evidence on differences between classes of drugs—and it is important to identify reliably the most effective drug therapy.
Drugs for Parkinson’s disease
  • A. Lees
  • Medicine
    Journal of neurology, neurosurgery, and psychiatry
  • 2002
Oldies but goodies It is chastening to reflect that although the portfolio of available drug treatments for Parkinson’s disease has multiplied, l-dopa, in its fourth decade of clinical use is still
Treatment Strategies in Early Parkinson's Disease.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 117 REFERENCES
Management of Parkinson's disease: An evidence‐based review
  • A. Lang, A. Lees
  • Medicine, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2002
TLDR
A systematic review of the literature dealing with the efficacy and safety of available treatments aimed at identifying those treatments for which there is sound scientific support to justify their application and to highlight where a lack of evidence points to the need for future clinical trials.
Ropinirole for the treatment of early Parkinson's disease
TLDR
Ropinirole monotherapy is an effective and well-tolerated therapeutic option for treatment of early Parkinson's disease and was a significantly greater percentage improvement in UPDRS motor score than patients who received placebo.
Quetiapine : A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease
TLDR
If dosage reduction of antiparkinsonian therapy does not alleviate psychotic symptoms in patients with Parkinson's disease, quetiapine may offer an effective alternative to other atypical antipsychotic agents, without compromising motor function.
The Sydney multicentre study of Parkinson’s disease
  • W. Poewe
  • Medicine, Psychology
    Journal of neurology, neurosurgery, and psychiatry
  • 1999
TLDR
A pivotal study on a cohort of 672 patients with “primary parkinsonism” came up with a rather bleak prognosis, with 61% of patients severely disabled or dead after 5 to 9 years of follow up, increasing to more than 80% of those who were followed up for more than 10 years.
Parkinson's disease: Cogentinr with sinemetr, a better response
Anti‐depressive treatment in Parkinson's disease A CONTROLLED TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH L‐DOPA
TLDR
The authors suggest the depression in Parkinson's disease to be of both reactive and endogenous origins.
Parkinson's disease: Cogentin with Sinemet, a better response.
TLDR
Qualitative and quantitative evaluations of relevant neurologic functions showed small, but statistically significant improvements for rigidity, finger tapping speed and activities of daily living in patients during the Sinemet plus benztropine mesylate treatment period.
Pergolide monotherapy in the treatment of early PD
TLDR
This study suggests that pergolide monotherapy may be an efficacious and well-tolerated first-line treatment in patients with early-stage PD.
Amantadine in Parkinson's disease
TLDR
A double-blind, placebo-controlled, crossover study with long-term follow-up of amantadine in Parkinson's disease resulted in a statistically significant 12 percent overall improvement over placebo.
...
1
2
3
4
5
...